We read the Stanford report released on May 15 2026 with concern and care. Medical researchers at Stanford University have highlighted five major health risks for adults over 65 who use modern high potency cannabis products. Their findings do not condemn all use but call for measured caution, clearer guidance from clinicians and better surveillance to protect older patients who face unique vulnerabilities from cardiovascular effects, medication interactions and cognitive and functional harms.
Why older adults are a distinct group
People over 65 metabolize drugs differently, carry more chronic conditions and take more prescription medicines than younger adults. Their bodies respond to psychoactive compounds with altered sensitivity. When cannabis products today can contain far higher concentrations of delta nine tetrahydrocannabinol per dose than decades past older users who expect modest effects may encounter stronger and longer lasting physiological responses. Stanford researchers emphasize that age related changes in liver and kidney function, along with shifting brain chemistry, raise the stakes for careful use and medical oversight.
Practical consequences we observed
From clinicians we spoke with the consequences are tangible: an older patient experiencing unexpected dizziness after trying a concentrated edible, another who delayed a critical medication because of uncertain interactions, and a caregiver watching once steady gait become tentative after recent use. These human moments anchor the report s clinical concerns and show why nuanced, age specific guidance is urgently needed.
Risk one: Cardiovascular events and instability
Stanford researchers flagged cardiovascular risk as a top concern. High potency cannabis can raise heart rate, affect blood pressure and in some cases trigger arrhythmias. For older adults with coronary artery disease, congestive heart failure or uncontrolled hypertension these effects can precipitate chest pain, shortness of breath and in rare instances acute cardiac events. The report recommends pre use cardiovascular screening and clinician discussion about dose, route of administration and monitoring when patients choose to use cannabis for symptom relief.
What patients and clinicians should do
Primary care physicians and cardiologists should ask older patients about cannabis use as explicitly as they ask about alcohol and tobacco. Patients with cardiac conditions should discuss lower dose approaches, avoid concurrent stimulants and seek immediate care for new chest symptoms after use.
Risk two: Drug interactions with common prescriptions
Older adults commonly take multiple medicines including anticoagulants statins antidepressants and drugs for diabetes. Cannabis compounds interact with liver enzymes responsible for drug metabolism which can raise or lower levels of other medications. The Stanford report details interactions that may increase bleeding risk when combined with blood thinners or alter blood sugar control in patients on insulin. These interactions are often under recognized in routine consultations.
Actionable steps for medication safety
Clinicians should review medication lists when patients report cannabis use and monitor for altered drug levels or side effects. Pharmacists can play a key role by checking for enzyme based interactions and advising on timing and dosing to minimize overlap. Where possible blood tests or clinical follow up should be arranged to detect early signs of interaction.
Risk three: Cognitive decline and acute confusion
Acute intoxication can cause confusion, impaired short term memory and slowed reaction times. For older adults who already have mild cognitive impairment or early dementia these effects can worsen functional independence, increase fall risk and complicate caregiving routines. The Stanford team noted that heavy or frequent use of high potency cannabis may accelerate cognitive complaints in some users and recommended conservative approaches and regular cognitive assessments for older patients who use or plan to use cannabis.
Balancing symptom relief and cognition
Some older adults use cannabis to manage chronic pain or insomnia. Clinicians should weigh potential cognitive trade offs and consider alternative pain management or sleep therapies when appropriate. If cannabis use proceeds, lower potency formulations, controlled dosing and daytime use avoidance can help reduce acute cognitive effects.
Risk four: Falls, mobility impairment and injuries
Dizziness, slowed reaction times and sedation can increase fall risk and worsen mobility problems common in older adults. The report ties several emergency department visits for fractures and head injuries to recent cannabis use among seniors. Because falls have outsized consequences for older adults, including loss of independence and higher mortality, preventing substance related fall risks is a public health priority.
Practical prevention tips
Start with the lowest effective dose and avoid using cannabis alone in environments where a fall would be dangerous. Mobility aids, supervision during initial trials and avoiding mixing with other sedatives such as benzodiazepines or high dose opioids are prudent steps. Occupational therapists and physiotherapists can help assess home safety if use is ongoing.
Risk five: Exacerbation of mental health and sleep disorders
While some people seek cannabis for anxiety or sleep problems, high potency products can backfire by increasing daytime anxiety, paranoia or fragmenting sleep architecture. Older adults with histories of mood disorders or psychosis are especially vulnerable to adverse psychiatric effects. The Stanford team recommends careful screening for mental health histories and prioritizing evidence based therapies where appropriate before or alongside cannabis trials.
Monitoring and support strategies
Mental health follow up during the early weeks of use can catch worsening symptoms quickly. Therapeutic options such as cognitive behavioral therapy for insomnia or structured anxiety treatments may provide safer, long term relief without exposure to psychoactive risks.
Policy implications and calls for research
Stanford researchers call for more age specific research, clearer clinical guidelines and stronger reporting systems for adverse events among older cannabis users. They want clinical trials that test lower dose strategies, different cannabinoid ratios and routes of administration to define safer use patterns. The report also urges regulators and dispensaries to provide clearer labeling and to fund clinician education so prescribing providers can counsel older patients with current evidence.
Where to find further guidance
Clinicians and patients can consult resources from established authorities such as the National Institutes of Health and specialist geriatric societies for evolving guidance on drug safety and substance use in older adults. For medication interaction checks the electronic drug interaction tools used by pharmacies remain essential and clinicians should keep up to date with cannabis specific interaction databases.
Practical advice for older adults considering cannabis
- Talk with your primary care doctor and review all medications before starting any cannabis product.
- Begin with very low doses, choose lower potency products and avoid edibles with delayed intense effects until you have tested a small amount under supervision.
- Avoid mixing cannabis with alcohol, sedatives or drugs that affect the heart and blood pressure without medical approval.
- Monitor for changes in cognition, mood and mobility and seek prompt medical advice if you notice concerning symptoms.
A human centered conclusion
The Stanford report is a clear call for cautious, informed choices for older adults and their clinicians. We must balance the genuine symptom relief that some patients report against measurable physiological risks amplified by age and polypharmacy. With better research, open clinician patient conversations and thoughtful policies, older adults can be protected while their autonomy in symptom management is respected. For now the safest course is careful medical review, conservative dosing and ongoing monitoring so that potential benefits do not come at the cost of avoidable harms.
